BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29748890)

  • 21. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer.
    Otowa Y; Nakamura T; Takiguchi G; Tomono A; Yamamoto M; Kanaji S; Imanishi T; Suzuki S; Tanaka K; Itoh T; Kakeji Y
    Dis Esophagus; 2016; 29(2):146-51. PubMed ID: 25515972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of postoperative pulmonary complications following salvage esophagectomy after definitive chemoradiotherapy.
    Hayami M; Watanabe M; Ishizuka N; Mine S; Imamura Y; Okamura A; Kurogochi T; Yamashita K
    J Surg Oncol; 2018 May; 117(6):1251-1259. PubMed ID: 29205358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
    Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
    Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
    World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
    Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H
    Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
    Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
    Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postoperative Infectious Complications are Associated with Adverse Oncologic Outcomes in Esophageal Cancer Patients Undergoing Preoperative Chemotherapy.
    Yamashita K; Makino T; Miyata H; Miyazaki Y; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2016 Jun; 23(6):2106-14. PubMed ID: 26753750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
    Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complications during neoadjuvant therapy and prognosis following surgery for esophageal cancer.
    Markar SR; Johar A; Maisey N; Lagergren P; Lagergren J
    Dis Esophagus; 2018 May; 31(5):. PubMed ID: 29293984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
    Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
    Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.